Gilead Sciences Inc. (GILD) Stock
NASDAQGILD has an Alpha Score of 50 out of 100 (weak), computed on Oct 28, 2026 from 3 of 4 sub-scores. 37 members of Congress disclosed 83 trades in GILD since 2014: 47 purchases and 36 sales, most recently Jared Moskowitz (purchase, May 6, 2026). 7 of the hedge funds AlphaScala tracks reported GILD in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $439.72M. Company insiders reported 0 open-market buys and 23 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 22.4 and its net margin -10.6% (key statistics as of Oct 22, 2026).
What is GILD's Alpha Score?
How it works →Alpha Score of 50 reflects weak overall profile with strong momentum, moderate value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 28, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Gilead Sciences Inc. (GILD)?
Most recent: Jared Moskowitz (purchase, May 6, 2026); records start Feb 6, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Jared Moskowitz D-FL · House | 2026-05-06 | purchase | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2026-01-27 | purchase | $1k – $15k |
| Val Hoyle D-OR · House | 2025-09-23 | sale | $1k – $15k |
| Marjorie Taylor Greene R-GA · House | 2025-06-06 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2025-05-14 | sale | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-05-12 | sale | $15k – $50k |
| Marjorie Taylor Greene R-GA · House | 2025-05-05 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded GILD, with filing lags →Which hedge funds own GILD?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 3.48M | $439.72M | -13% |
| D.E. Shaw David Shaw | 2.29M | $289.92M | +1042% |
| Renaissance Technologies Jim Simons (founder) | 2.22M | $280.14M | +3% |
| Millennium Management Israel Englander | 1.46M | $184.32M | +24% |
| Point72 Steve Cohen | 1.44M | $181.64M | +16222% |
| Bridgewater Associates Ray Dalio | 291K | $36.75M | +61% |
| Marshall Wace | 205K | $25.86M | -91% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Gilead Sciences Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Dickinson Andrew D | Chief Financial Officer | SELL | 3.0K | $469K |
| Oct 15, 26 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 3.0K | $469K |
| Oct 1, 26 | O'Day Daniel Patrick | Chairman & CEO | SELL | 12.0K | $1.8M |
| Oct 1, 26 | O'Day Daniel Patrick | Chairman & CEO | SELL | 3.0K | $446K |
| Sep 15, 26 | Dickinson Andrew D | Chief Financial Officer | SELL | 3.0K | $436K |
| Sep 15, 26 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 1.6K | $230K |
| Sep 15, 26 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 800 | $116K |
| Sep 15, 26 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 600 | $87K |
| Sep 1, 26 | O'Day Daniel Patrick | Chairman & CEO | SELL | 1.6K | $236K |
| Sep 1, 26 | O'Day Daniel Patrick | Chairman & CEO | SELL | 8.0K | $1.2M |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are GILD's key statistics?
Key statistics as of Oct 22, 2026
How does GILD's valuation compare with the Healthcare sector?
| Metric | GILD | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 22.4 | 27.1 | 97 |
| Net margin | -10.64% | 5.48% | 139 |
| Return on equity | -16.30% | 6.84% | 158 |
| Dividend yield (payers) | 3.98% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
AlphaScala analysis on GILD
Latest 1GILD price chart
Powered by TradingViewWhat does Gilead Sciences Inc. do?
Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines addressing unmet medical needs in infectious diseases, oncology, and other therapeutic areas across the United States, Europe, and international markets. Its portfolio centers on HIV treatments, including leading products like Biktarvy, Genvoya, Descovy, Odefsey, Sunlenca, and Yeztugo, the world's first twice-yearly HIV prevention therapy. The company also offers therapies for viral hepatitis such as Epclusa, Harvoni, Vemlidy, and Viread, alongside Veklury for COVID-19. In oncology and cell therapy, Gilead provides Yescarta, Tecartus, and Trodelvy for various cancers, as well as Livdelzi for primary biliary cholangitis. These products target life-threatening conditions in virology, liver diseases, hematology, inflammation, and respiratory areas, serving patients through innovative antiviral regimens, CAR-T cell therapies, and antibody-drug conjugates. Founded in 1987 and headquartered in Foster City, California, Gilead Sciences Inc. plays a pivotal role in advancing treatments for chronic and infectious diseases globally.